AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16006907 — intervention group
Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 24
Study 11788983 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 derived preference scores
Number of subjects: 379
Study 11788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly elicited time trade off (TTO)
Number of subjects: 379
Study 11788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 379
Study 11788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice based methods (standard gamble, TTO)
Number of subjects: 379
Study 11788983 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 derived preferences
Number of subjects: 379
Study 10469094 — intervention group
Group type: EXPERIMENTAL
Intervention: 950 microsec dwell time CO2 laser
Number of subjects: 20
Study 10469094 — intervention group
Group type: COMPARATOR
Intervention: Manual tumescent dermabrasion
Number of subjects: 20
Study 7571059 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 134
Study 7571059 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (no RT)
Number of subjects: 134
Study 2147913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 0
Study 2147913 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 0
Study 7016800 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 21 657 (3 X 400 mg/day p.o.) + maprotiline (75 mg/day p.o.)
Number of subjects: 40
Study 7016800 — intervention group
Group type: COMPARATOR
Intervention: maprotiline (75 mg/day p.o.)
Number of subjects: 40
Study 31103560 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 277
Study 31103560 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 277
Study 30449754 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine imaging of the fundus and optic nerve followed by a complete eye exam
Number of subjects: 182
Study 30449754 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete eye exam after telemedicine screening
Number of subjects: 182
Study 30449754 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine imaging of the fundus and optic nerve
Number of subjects: 182
Study 25995159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette Dependence Scale (CDS-5)
Number of subjects: 476
Study 25995159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerström Test for Cigarette Dependence (FTCD)
Number of subjects: 476
Study 23806488 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted plus active cranio‐cervical flexion exercise
Number of subjects: 18
Study 23806488 — intervention group
Group type: COMPARATOR
Intervention: Passive mobilisation plus assisted cranio‐cervical flexion
Number of subjects: 18
Study 22427507 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention (individual counselling, Coping with Depression course, referral to general practitioner if indicated)
Number of subjects: 239
Study 22427507 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 239
Study 20222004 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-leg squat jumps in water
Number of subjects: 12
Study 20222004 — intervention group
Group type: COMPARATOR
Intervention: Two-leg squat jumps on dry land
Number of subjects: 12
Study 17655672 — intervention group
Group type: EXPERIMENTAL
Intervention: POST intervention group
Number of subjects: 330
Study 16117464 — intervention group
Group type: EXPERIMENTAL
Intervention: Embol-X intra-aortic filter
Number of subjects: 146
Study 16117464 — intervention group
Group type: COMPARATOR
Intervention: Conventional cannulation (Control)
Number of subjects: 146
Study 12712491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 90 mg
Number of subjects: 60
Study 12712491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11021961 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions
Number of subjects: 10
Study 11021961 — intervention group
Group type: COMPARATOR
Intervention: Eccentric contractions
Number of subjects: 10
Study 8615350 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCFAs
Number of subjects: 59
Study 8615350 — intervention group
Group type: COMPARATOR
Intervention: Control (LLA)
Number of subjects: 59
Study 1333500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing 3, 6, or 9 oz of beef
Number of subjects: 0
Study 1333500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing beef
Number of subjects: 0
Study 1333500 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 0
Study 6711779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg/kg orally given 120-180 minutes pre-operatively
Number of subjects: 100
Study 6711779 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 6711779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg/kg orally
Number of subjects: 100
Study 30132204 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Frailty Index (eFI) derived from electronic health records (EHRs)
Number of subjects: 60
Study 30132204 — intervention group
Group type: COMPARATOR
Intervention: Fried's frailty phenotype (reference standard)
Number of subjects: 60
Study 30132204 — intervention group
Group type: EXPERIMENTAL
Intervention: Data extraction from EHRs
Number of subjects: 60
Study 30132204 — intervention group
Group type: EXPERIMENTAL
Intervention: EHRs of patients with multiple health problems
Number of subjects: 60
Study 29141848 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC protein expression (top vs bottom quartile)
Number of subjects: 634
Study 29141848 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC mRNA expression
Number of subjects: 634
Study 29141848 — intervention group
Group type: COMPARATOR
Intervention: MYC protein expression
Number of subjects: 634
Study 27815799 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) - 2 daily 1.25 g capsules (totaling about 2 g of CLA in glycerinated form)
Number of subjects: 52
Study 27815799 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 2 daily 1.25 g capsules containing sunflower oil with high oleic acid
Number of subjects: 52
Study 24966099 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 52
Study 24966099 — intervention group
Group type: EXPERIMENTAL
Intervention: double HIT
Number of subjects: 52
Study 22429192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix
Number of subjects: 233
Study 22429192 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin (control)
Number of subjects: 233
Study 20155787 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course RT (5 x 5 Gy) and surgery within 1 week (group 1)
Number of subjects: 303
Study 20155787 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course RT (5 x 5 Gy) and surgery after 4-8 weeks (group 2)
Number of subjects: 303
Study 20155787 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-course RT (25 x 2 Gy) and surgery after 4-8 weeks (group 3)
Number of subjects: 303
Study 20155787 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course RT with surgery 11-17 days after the start of RT
Number of subjects: 303
Study 20155787 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 303
Study 18948798 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 164
Study 18948798 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 164
Study 15756252 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1150 mg m‐2 twice daily with irinotecan 250 mg m‐2
Number of subjects: 27
Study 15756252 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg m‐2 with irinotecan 250 mg m‐2
Number of subjects: 27
Study 15756252 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI regimen (capecitabine and irinotecan)
Number of subjects: 27
Study 15756252 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and irinotecan combination therapy
Number of subjects: 27
Study 15756252 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI regimen
Number of subjects: 27
Study 12540205 — intervention group
Group type: EXPERIMENTAL
Intervention: Length-normalized pulse photoplethysmography (D/l)
Number of subjects: 25
Study 9681402 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg HBOC‐201
Number of subjects: 12
Study 9681402 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (mw 70,000)
Number of subjects: 12
Study 9681402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HBOC‐201 and hydroxyethyl starch)
Number of subjects: 12
Study 7988131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g every 8 hrs)
Number of subjects: 26
Study 7988131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL of sterile water every 8 hrs)
Number of subjects: 26
Study 2521989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms)
Number of subjects: 13
Study 2521989 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study 2521989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (lower doses)
Number of subjects: 13
Study 4567765 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (dosage and smoking procedure standardized)
Number of subjects: 81
Study 4567765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dosage and smoking procedure standardized)
Number of subjects: 81
Study 30169915 — intervention group
Group type: EXPERIMENTAL
Intervention: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PI (30% weekly plus 5% daily increments)
Number of subjects: 101
Study 30169915 — intervention group
Group type: EXPERIMENTAL
Intervention: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PII (30% weekly increments)
Number of subjects: 101
Study 30169915 — intervention group
Group type: COMPARATOR
Intervention: Control group (egg-free diet)
Number of subjects: 101
Study 29619533 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (600 mg/day)
Number of subjects: 36
Study 29619533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26706022 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements (n = 20)
Number of subjects: 40
Study 26706022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 24063317 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 individual life review sessions and co‐creating a life story book (LSB)
Number of subjects: 23
Study 24063317 — intervention group
Group type: COMPARATOR
Intervention: Personal LSB created by their relatives as a 'gift'
Number of subjects: 23
Study 24063317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pathways of creating LSBs
Number of subjects: 23
Study 21094258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal 2.0 mA tDCS for 30 min over right inferior frontal and right parietal cortex
Number of subjects: 96
Study 21094258 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mA tDCS
Number of subjects: 96
Study 21094258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal 2.0 mA tDCS
Number of subjects: 96
Study 20432043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound turbinate reduction
Number of subjects: 60
Study 20432043 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency coblation technique
Number of subjects: 60
Study 20432043 — intervention group
Group type: COMPARATOR
Intervention: Monopolar diathermy (electrocautery)
Number of subjects: 60
Study 17509869 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group EA) with a 7‐mL epidural bolus 0.1% bupivacaine containing fentanyl 50 mug (n=20)
Number of subjects: 40
Study 17509869 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal‐epidural analgesia (group CSEA) with intrathecal fentanyl 20 mug (n=20)
Number of subjects: 40
Study 16450805 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical evacuation
Number of subjects: 0
Study 16450805 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal access surgical techniques
Number of subjects: 0
Study 16450805 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic aspirations
Number of subjects: 0
Study 16450805 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and thorough clot evacuation
Number of subjects: 0
Study 16450805 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques or adjuvant medical treatment to reduce clot expansion and rebleeding
Number of subjects: 0
Study 12523676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6321
Study 12523676 — intervention group
Group type: COMPARATOR
Intervention: Co-amilozide
Number of subjects: 6321
Study 9700469 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride emulsion infusion (Lipid infusion study)
Number of subjects: 9
Study 9700469 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Saline infusion study)
Number of subjects: 9
Study 7623616 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-979 (0.5-mg q6h, 1-mg q12h, 1-mg q6h, 2-mg q12h, 2-mg q6h, 2.5-mg q6h, and 3-mg q6h)
Number of subjects: 10
Study 7623616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional (C) propranolol 160 mg
Number of subjects: 24
Study 2569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting (LA) propranolol 160 mg
Number of subjects: 24
Study 2569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 24
Study 2569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol pharmacology
Number of subjects: 24
Study 2569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol concentration
Number of subjects: 24
Study 913256 — intervention group
Group type: EXPERIMENTAL
Intervention: Alorbat
Number of subjects: 893
Study 913256 — intervention group
Group type: EXPERIMENTAL
Intervention: Begrivac S
Number of subjects: 893
Study 7176839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients with CAH (total group)
Number of subjects: 477
Study 7176839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients with cirrhosis and CAH (Group I A)
Number of subjects: 477
Study 7176839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients with probably cirrhosis and CAH (Group I B)
Number of subjects: 477
Study 7176839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients compatible with but not diagnostic for cirrhosis and CAH (Group I C)
Number of subjects: 477
Study 7176839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients without CAH (Group II A + B + C)
Number of subjects: 477
Study 7176839 — intervention group
Group type: COMPARATOR
Intervention: Control patients with CAH in all three subgroups
Number of subjects: 477
Study 31543318 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THR)
Number of subjects: 105
Study 31543318 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 105
Study 28323796 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern ring external fixation
Number of subjects: 0
Study 28323796 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 0
Study 27446999 — intervention group
Group type: EXPERIMENTAL
Intervention: Calaject system (controlled flow technique)
Number of subjects: 25
Study 27446999 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe (control side)
Number of subjects: 25
Study 24099893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablets (FBTs)
Number of subjects: 0
Study 24099893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22676248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapro mesh
Number of subjects: 0
Study 22676248 — intervention group
Group type: COMPARATOR
Intervention: Prolene mesh
Number of subjects: 0
Study 19322503 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (RTx)
Number of subjects: 351
Study 19322503 — intervention group
Group type: COMPARATOR
Intervention: No external beam radiotherapy (non-RTx)
Number of subjects: 351
Study 17308893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily with oral etoposide starting at 50 mg every other day
Number of subjects: 32
Study 17308893 — intervention group
Group type: COMPARATOR
Intervention: Oral etoposide alone (baseline pharmacokinetic studies)
Number of subjects: 32
Study 17308893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily with oral etoposide
Number of subjects: 32
Study 12877651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with arachidonic acid (AA) at a dosage of 4 g/day for 8 weeks
Number of subjects: 0
Study 12877651 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (OA) supplementation
Number of subjects: 0
Study 11161542 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY-GLN (500 ml glycyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Number of subjects: 30
Study 11161542 — intervention group
Group type: COMPARATOR
Intervention: Control (1500 ml Vamin)
Number of subjects: 30
Study 11161542 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-GLN (500 ml alanyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Number of subjects: 30
Study 9587049 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovir (400 mg)
Number of subjects: 24
Study 9587049 — intervention group
Group type: COMPARATOR
Intervention: Zovirax (400 mg)
Number of subjects: 24
Study 7934013 — intervention group
Group type: EXPERIMENTAL
Intervention: Meso-ectomorphs (n = 65)
Number of subjects: 180
Study 7934013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesomorphs (n = 50)
Number of subjects: 180
Study 7934013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectomorphs (n = 25)
Number of subjects: 180
Study 7934013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectomesomorphs (n = 40)
Number of subjects: 180
Study 7934013 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall injuries recorded
Number of subjects: 180
Study 3192889 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric consultation
Number of subjects: 451
Study 4629183 — intervention group
Group type: EXPERIMENTAL
Intervention: D.S.C.G.-isoprenaline
Number of subjects: 74
Study 4629183 — intervention group
Group type: EXPERIMENTAL
Intervention: D.S.C.G.
Number of subjects: 74
Study 4629183 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 74
Study 4629183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 4629183 — intervention group
Group type: EXPERIMENTAL
Intervention: D.S.C.G.-isoprenaline and D.S.C.G.
Number of subjects: 74
Study 4629183 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dosage
Number of subjects: 74
Study 4629183 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing regimen
Number of subjects: 74
Study 31821109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus trastuzumab (CRxT)
Number of subjects: 3270
Study 31821109 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone (CRx)
Number of subjects: 3270
Study 31169661 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SAM
Number of subjects: 430
Study 31169661 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 430
Study 28017167 — intervention group
Group type: COMPARATOR
Intervention: PEEP 5 group
Number of subjects: 43
Study 28017167 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 group
Number of subjects: 43
Study 25807902 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth therapy (complete scaling and root planing in one stage within 24 h)
Number of subjects: 180
Study 25807902 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (scaling and root planing performed by quadrant over a period of 4 weeks)
Number of subjects: 180
Study 23927056 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral Body Stenting (VBS) system
Number of subjects: 100
Study 21324193 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 110
Study 21324193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 19697106 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion system (ME3) containing 50% water
Number of subjects: 0
Study 19697106 — intervention group
Group type: COMPARATOR
Intervention: Oral dosage form of tolterodine tartrate
Number of subjects: 0
Study 17112848 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 152
Study 14760340 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (200 microg/kg intravenously, followed by 30 mg/d orally)
Number of subjects: 32
Study 14760340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10547171 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Compliance Program (ECP)
Number of subjects: 125
Study 10547171 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 8678058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg once daily
Number of subjects: 70
Study 8678058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1997054 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg in elixir formulation
Number of subjects: 100
Study 1997054 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 30 mg in capsule formulation
Number of subjects: 100
Study 6519348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg b.i.d.
Number of subjects: 50
Study 6519348 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 50
Study 29752593 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallidinogenase (150 units administered daily for 52 weeks)
Number of subjects: 39
Study 29752593 — intervention group
Group type: COMPARATOR
Intervention: No kallidinogenase (control group)
Number of subjects: 39